NHS warning for Mounjaro users: Oral medicines like contraception and HRT may not work as expected

• What happened: The UK’s NHS has issued a safety warning for people using Mounjaro (tirzepatide) alongside oral medications.

• Why it matters now: Use of weight loss injections is rising sharply, increasing the risk of reduced effectiveness of key medicines.

• What changes for people: Users may need to switch from oral pills to alternative methods or add temporary protection.

• Who is affected: Women on contraceptive pills, HRT users, and patients taking daily oral medicines.

The National Health Service (NHS) has cautioned that Mounjaro, a widely used weight loss injection, can interfere with how the body absorbs oral medicines, including contraceptive pills and hormone replacement therapy (HRT). The alert comes as thousands turn to injectable treatments for weight management at the start of the year.

Why Mounjaro affects oral medicines

Mounjaro works by slowing stomach emptying, helping users feel full for longer and reduce calorie intake.
However, NHS guidance explains that this same effect can delay or reduce absorption of tablets, meaning pills may not work as intended.

The NHS has highlighted this issue on its official platforms, urging patients to inform clinicians about all medicines they take before starting or increasing doses.

Contraceptive pill risks explained

Health officials say the progesterone-only contraceptive pill is at highest risk of reduced effectiveness when taken with Mounjaro.

The NHS advises:

• Switch to non-oral contraception such as coils or implants, or

• Use condoms for at least four weeks after starting Mounjaro or after any dose increase

If vomiting occurs within three hours of taking a pill, or if diarrhoea lasts more than 24 hours, standard missed pill rules should be followed.

Doctors warn that failing to adjust contraception could lead to unplanned pregnancies or breakthrough bleeding.

What HRT users should know

People using oral progesterone-based HRT, including medicines like Utrogestan or norethisterone, may also face reduced hormone absorption.

Specialists caution this could cause irregular bleeding and, in some cases, inadequate womb protection, which may increase the risk of endometrial complications.

Clinicians are advising reviews to consider non-oral HRT options, such as gels or patches, to maintain consistent hormone levels.

NHS rollout and private use

The NHS is currently offering Mounjaro through specialist weight management services, mainly for patients with severe obesity, defined as a BMI over 40, or over 35 with related health conditions.
It is not yet widely prescribed by GPs.

Meanwhile, private prescriptions have surged, prompting NHS officials to stress the importance of full medication disclosure before starting treatment.

Common side effects such as nausea, vomiting, and diarrhoea often ease over time, but they can further disrupt how oral medicines work.

What to watch next

• Updated clinical guidance on managing contraception and HRT with weight loss injections

• Possible broader NHS prescribing access for Mounjaro

• Increased focus on patient education around drug interactions and safe use